Indiana is currently home to 1256 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Indianapolis, South Bend, Fort Wayne and Evansville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers
NCT05255107
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of previously untreated corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Riboflavin 0.23% PESCHKE-L Solution) administered in conjunction with the UV-A li... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Keratitis, Corneal Ulcer
Register for Updates
Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers
NCT05255016
Recruiting
This study is being conducted to evaluate the safety and effectiveness of using the PXL Platinum 330 System with riboflavin solution for performing corneal collagen crosslinking (CXL) for the treatment of refractory corneal ulcers. The PXL Platinum 330 System is a combination product consisting of an ultraviolet-A (UV-A) 365 nm wavelength light source (PXL Platinum 330 Illumination System) and riboflavin (Peschke Riboflavin 0.25% Transepithelial Solution) administered in conjunction with the UV-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/26/2022
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Keratitis, Corneal Ulcer
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/25/2022
Locations: St. Vincent Anderson Regional Hospital Research, Anderson, Indiana
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
NCT01860612
Recruiting
The purpose of this study is to study the long term safety and effectiveness of an artificial iris prosthesis for the treatment of iris defects.
Gender:
All
Ages:
3 years and above
Trial Updated:
10/21/2022
Locations: Price Vision Group, Indianapolis, Indiana
Conditions: Full Aniridia, Partial Aniridia
Register for Updates
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
NCT03926624
Recruiting
Phase III, multicenter, randomized study with two arms (1:1 ratio) enrolling patients with AML relapsed/refractory after 2, 3, or 4 prior induction regimens: Experimental arm: DFP-10917 14-day continuous intravenous (IV) infusion at a dose of 6 mg/m²/day followed by a 14-day resting period per 28-day cycles. Control arm: Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens), dependin... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2022
Locations: Franciscan Health Indianapolis, Indianapolis, Indiana
Conditions: Leukemia, Myeloid, Acute
Register for Updates
Critical Health Assessment and Outcomes Score/Study
NCT02766166
Recruiting
CHAOS is based on the investigator's new and exciting results from pre-clinical and large longitudinal multi-center observational clinical studies of critically ill patients and asymptomatic community-based adults with little or no advanced disease. By integrating approaches from the physical, biological, computational, statistical and clinical sciences, this observational study will test the hypothesis that early diagnosis of subclinical signatures of critical illness encoded within physiologi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/07/2022
Locations: Indiana University, Indianapolis, Indiana
Conditions: Critical Illness, Death, Sudden
Register for Updates
Surveillance AFter Extremity Tumor surgerY
NCT03944798
Recruiting
Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impac... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/04/2022
Locations: Parkview Cancer Institute, Fort Wayne, Indiana
Conditions: Soft Tissue Sarcoma, Lung Metastases
Register for Updates
Late Onset Alzheimer's Disease
NCT05010603
Recruiting
The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.
Gender:
All
Ages:
55 years and above
Trial Updated:
09/16/2022
Locations: Indiana University, Bloomington, Indiana
Conditions: Alzheimer Disease
Register for Updates
Rare and Atypical Diabetes Network
NCT05544266
Recruiting
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical di... Read More
Gender:
All
Ages:
All
Trial Updated:
09/14/2022
Locations: Indiana University, Indianapolis, Indiana
Conditions: Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Register for Updates
Leg Heat Therapy in Elderly Individuals
NCT05543980
Recruiting
The number of persons aged ≥60 years in the United States is expected to nearly double, from 57 to 109 million between 2010 and 2050. These demographic changes will have profound implications for the healthcare system because advanced age is associated with a heightened risk of negative health outcomes, including disability and frailty. Few therapeutic strategies currently exist to combat the age-related decline in physical functioning that stems from the progressive loss of muscle mass and stre... Read More
Gender:
All
Ages:
65 years and above
Trial Updated:
09/13/2022
Locations: Purdue University, West Lafayette, Indiana
Conditions: Aging, Muscle Weakness
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: ASHA Clinical Research, Hammond, Indiana
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
Gender:
All
Ages:
18 years and above
Trial Updated:
08/03/2022
Locations: Goshen Center for Cancer Care, Goshen, Indiana
Conditions: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
Register for Updates